Hey Dew:
<<RVNC is looking for commercial partners in Europe and Asia/Pacific (which could be the same company).>>
Can we infer from this that they won't be seeking a North American partner? If they were, wouldn't they be looking there as well? What odds would you give to go it alone strategy in US/NA? As a shareholder, which would you prefer and why?
Also, question regarding the China deal. From the press release:
<<Fosun Pharma Industrial will be responsible for conducting necessary clinical studies, marketing and sales in the Territory, while Revance will be responsible for manufacturing>>
Confused about what this statement means regarding new clinical trials as it seems to contradict their statement below:
<<Fosun Pharma already has a growing portfolio of products in facial aesthetics where we plan to gain the first approval for RT002>>
Why would approval be first in China? Are new trials needed there in addition to the 3 phase 3's already completed? When do they forecast a China approval?
